List of Excipients in Branded Drug METHYLPHENIDATE EXTENDED-RELEASE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Neos Therapeutics LP	METHYLPHENIDATE EXTENDED-RELEASE	methylphenidate extended-release	62542-100	CELLULOSE, MICROCRYSTALLINE
Neos Therapeutics LP	METHYLPHENIDATE EXTENDED-RELEASE	methylphenidate extended-release	62542-100	CITRIC ACID MONOHYDRATE
Neos Therapeutics LP	METHYLPHENIDATE EXTENDED-RELEASE	methylphenidate extended-release	62542-100	CROSPOVIDONE

Methylphenidate Extended-Release Excipient Strategy and Commercial Opportunities

Last updated: August 28, 2026

Methylphenidate extended-release is a formulation-driven market rather than a single-product market. Commercial differentiation depends on release profile, abuse-deterrence characteristics, dose flexibility, administration timing, pediatric usability, and generic substitutability. The largest excipient opportunities are in multiparticulate coatings, osmotic delivery systems, taste masking, capsule-in-capsule technologies, orally disintegrating tablets, and modified-release matrices.

What products compete in the methylphenidate extended-release market?

Methylphenidate extended-release products use different delivery technologies and therefore create separate excipient and patent opportunities.

Product	Active ingredient	Dosage form	Release technology	Key commercial attribute
Concerta	Racemic methylphenidate HCl	Osmotic ER tablet	OROS push-pull system	Once-daily delivery with ascending release profile
Ritalin LA	Racemic methylphenidate HCl	Capsule with beads	SODAS-like biphasic bead system	Two release pulses
Metadate CD	Racemic methylphenidate HCl	Capsule with beads	Immediate-release and delayed-release beads	Flexible sprinkle administration
Aptensio XR	Racemic methylphenidate HCl	Capsule with coated beads	Multi-layer bead technology	Extended coverage and sprinkle option
Quillivant XR	Racemic methylphenidate HCl	Oral suspension	Ion-exchange resin and polymer-controlled release	Liquid administration
Quillichew ER	Racemic methylphenidate HCl	Chewable tablet	Modified-release matrix	Pediatric chewable dosage form
Cotempla XR-ODT	d-Methylphenidate HCl	Orally disintegrating tablet	XR-ODT multiparticulate technology	No-water administration
Jornay PM	Methylphenidate HCl	Delayed-release/ER capsule	Evening-dose, delayed-onset multiparticulate system	Morning symptom control
Azstarys	Serdexmethylphenidate/d-methylphenidate	Capsule	Prodrug plus immediate-release d-methylphenidate	Long duration; not a conventional methylphenidate-only product

FDA-approved labeling identifies the excipient composition, dosage form, administration instructions, and release characteristics for each product.[1-8]

The commercial market is segmented by release architecture:

1. Conventional once-daily extended release.
2. Biphasic or pulsatile release.
3. Delayed-onset evening dosing.
4. Liquid and chewable pediatric delivery.
5. Orally disintegrating delivery.
6. Sprinkle-compatible capsules.

These segments do not have interchangeable excipient requirements. A formulation designed for a generic osmotic tablet cannot be readily adapted to a liquid suspension or an orally disintegrating tablet.

Which excipient technologies are most important for methylphenidate extended-release?

The highest-value excipient strategy combines release control with manufacturability and dose uniformity.

Hydrophilic and hydrophobic matrix systems

Matrix tablets can use hypromellose, polyethylene oxide, ethylcellulose, glyceryl behenate, stearic acid, or related release-controlling materials. Hydrophilic matrices hydrate after administration and form a gel layer. Hydrophobic materials reduce water penetration and drug diffusion.

For methylphenidate, matrix approaches must address:

• High dose-to-tablet-size constraints.
• Dose dumping risk.
• Mechanical integrity during compression.
• Food-effect control.
• Reproducible release across pH conditions.
• Resistance to crushing or unintended manipulation.

Hydrophilic polymer grade, viscosity, particle size, substitution level, and supplier variability can materially change dissolution. Excipient suppliers with narrow lot-to-lot specifications can obtain a stronger position than suppliers offering only commodity hypromellose.

Osmotic delivery excipients

OROS-type systems use a semipermeable membrane, osmotic agents, a drug layer, and a push layer. Typical functional materials include:

• Polyethylene oxide as a swellable push-layer polymer.
• Sodium chloride or another osmogen.
• Cellulose acetate as a semipermeable membrane.
• Polyethylene glycol as a membrane pore former or coating modifier.
• Film coatings and colorants.
• Lubricants and compression aids.

The commercial barrier is not the individual excipient. It is the integrated manufacturing process, including bilayer compression, membrane coating, laser orifice formation, and in-process control. Patent protection historically has focused on the delivery architecture and manufacturing method rather than only on the chemical identity of the excipients.

Multiparticulate bead systems

Ritalin LA, Metadate CD, Aptensio XR, Jornay PM, and similar products rely on coated drug-loaded particles or beads. The formulation platform may include:

• Sugar spheres or microcrystalline cellulose cores.
• Drug-layering binders such as povidone or hydroxypropyl cellulose.
• Ethylcellulose or ammonio methacrylate copolymers for sustained release.
• Enteric polymers such as methacrylic acid copolymers for delayed release.
• Talc or colloidal silicon dioxide as anti-tacking agents.
• Plasticizers such as triethyl citrate or polyethylene glycol.
• Capsule shells, colorants, and printing inks.

Multiparticulate systems provide a broad design space. Release can be adjusted by coating thickness, polymer ratio, pore former level, bead size, and the ratio of immediate-release to modified-release populations.

This platform creates commercial opportunities for specialty excipients with validated pharmaceutical grades, low residual solvents, narrow particle-size distributions, and reproducible coating performance.

Taste masking and pediatric excipients

Liquid, chewable, and orally disintegrating products require taste control because methylphenidate has an unacceptable bitter profile for many pediatric patients.

Relevant strategies include:

• Ion-exchange resin complexes.
• Polymer film coating.
• Lipid or wax barriers.
• Cyclodextrin complexation.
• Sweetener and flavor systems.
• Saliva-triggered or pH-triggered release.
• Microencapsulation.
• Low-moisture excipient systems.

Taste masking cannot compromise the intended intestinal or extended-release profile. A coating that works in a chewable tablet may not work in an oral suspension because agitation, sedimentation, and residence time differ.

For pediatric products, excipients must also support:

• Dose uniformity after shaking.
• Redispersibility.
• Palatability over the labeled shelf life.
• Low sedimentation or controlled sedimentation.
• Preservative compatibility.
• Accurate dosing with an oral syringe.
• Low tablet friability for chewable or ODT products.

What excipients are disclosed in methylphenidate extended-release labels?

FDA labels provide a practical starting point for competitive excipient mapping. The exact composition differs by product and manufacturing site.

Product	Representative excipient categories disclosed in labeling	Formulation role
Concerta	Polyethylene oxide, cellulose acetate, hypromellose, sodium chloride, polyethylene glycol, iron oxides, lactose-related tablet components	Osmotic push layer, membrane, osmogen, coating
Ritalin LA	Sugar spheres, hypromellose, methacrylic acid copolymers, polyethylene glycol, talc, gelatin	Drug layering, delayed release, bead coating
Metadate CD	Sugar spheres, povidone, hypromellose, ethylcellulose, polyethylene glycol, talc, gelatin	Immediate- and extended-release bead populations
Quillivant XR	Ion-exchange resin, suspending agents, sweeteners, flavors, preservatives	Resin complexation, suspension stability, taste masking
Quillichew ER	Polymer matrix materials, compression aids, sweeteners, flavors, colorants	Chewability, modified release, palatability
Cotempla XR-ODT	Drug-loaded microparticles, mannitol and other ODT excipient classes, polymers, sweeteners, flavors	Rapid disintegration with extended-release particles
Jornay PM	Coated multiparticulates, delayed-release polymers, sustained-release polymers, capsule excipients	Evening dosing and delayed morning onset

The table is categorical rather than a substitute for the current package insert. Exact excipient identity and quantitative composition can change by product presentation and labeling revision.[1-7]

What formulation patents protect methylphenidate extended-release products?

Methylphenidate extended-release patent protection is usually concentrated in five areas.

Delivery architecture patents

These cover the physical system that controls drug release. Examples include osmotic tablets, coated beads, multi-layer particles, and capsule systems containing distinct release populations.

The most important historical example is the OROS platform associated with Concerta. Relevant patent families include U.S. Patent Nos. 5,837,284 and 6,919,373, although enforceability, expiration, terminal disclaimers, and Orange Book listing status must be analyzed by claim and product.[9,10]

Polymer and coating combinations

Patents may claim specific combinations of:

• Ethylcellulose or methacrylate polymers.
• Plasticizers and pore formers.
• Coating weight gain.
• Immediate-release and delayed-release bead ratios.
• Dissolution windows at defined pH conditions.
• Particle-size distributions.
• Drug loading levels.

These claims can create barriers even when the active ingredient is old and unpatented.

Delayed-onset and chronotherapy patents

Jornay PM is differentiated by evening administration and delayed morning release. Its patent position is more closely connected to the timing profile and coated multiparticulate system than to methylphenidate chemistry alone. The commercial value lies in achieving low overnight release followed by morning and daytime exposure.[7]

Dosage-form patents

Chewable tablets, liquid suspensions, ODTs, and sprinkle capsules can have separate patent positions. Dosage-form claims may cover:

• A specified disintegration time.
• A defined dissolution profile.
• Taste-masked particles.
• Stable oral suspensions.
• Dose uniformity after shaking.
• Administration without water.
• Particles that pass through food without altering release.

Manufacturing-process patents

Process claims may cover drug layering, fluid-bed coating, bilayer compression, membrane formation, laser drilling, particle classification, and capsule filling. These patents can be commercially important even when a competitor uses similar excipients.

When does methylphenidate extended-release lose exclusivity?

There is no single methylphenidate extended-release exclusivity date. Each branded product has its own FDA exclusivity, Orange Book patent listings, regulatory history, and generic competition.

Product or platform	Primary risk issue	Practical exclusivity analysis
Concerta	OROS formulation and release-profile patents	Generic competition has existed, but substitutability and therapeutic-equivalence history have varied
Ritalin LA	Bead formulation and capsule release profile	ANDA applicants must match the multiparticulate performance
Metadate CD	Biphasic bead composition	Release-population matching is central
Quillivant XR	Liquid suspension, resin complex, stability, taste	Manufacturing and equivalence are more difficult than for a simple tablet
Quillichew ER	Chewable modified-release matrix	Palatability, mechanical properties, and dissolution create differentiation
Cotempla XR-ODT	ODT and extended-release microparticles	Disintegration and release must be matched simultaneously
Jornay PM	Delayed-onset evening-dose profile	Timing of release is the core competitive barrier

FDA regulatory exclusivity for many older methylphenidate products has expired. The remaining barriers are generally product-specific patents, ANDA development requirements, manufacturing complexity, controlled-substance controls, and physician or payer preference.

What is the Orange Book status of methylphenidate extended-release products?

The Orange Book does not list "methylphenidate extended-release" as one unified patent estate. It lists patents and exclusivity associated with individual reference-listed drugs.

For commercial diligence, the relevant review should cover:

1. The exact reference product and dosage form.
2. Active and inactive ingredient differences.
3. Listed patents and expiration dates.
4. Patent-use codes for method-of-use claims.
5. Whether a patent has been delisted, expired, or disclaimed.
6. Whether an ANDA applicant filed a Paragraph IV certification.
7. The therapeutic-equivalence rating of marketed generics.
8. Any FDA decision affecting substitutability.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed. The certification can trigger patent litigation under the Hatch-Waxman Act. A timely suit can impose a 30-month stay, subject to statutory exceptions and court action.[11]

Concerta illustrates the importance of separating FDA substitutability from patent expiration. FDA has changed therapeutic-equivalence determinations for certain extended-release methylphenidate products over time. A generic may be approved yet not automatically substitutable for every branded presentation.

Which companies are challenging methylphenidate extended-release products?

Generic and specialty pharmaceutical companies have pursued several product categories:

• Osmotic extended-release tablets comparable to Concerta.
• Biphasic bead capsules comparable to Ritalin LA or Metadate CD.
• Extended-release oral suspensions.
• Chewable extended-release tablets.
• ODT products.
• Delayed-onset capsules.

Historical and current participants have included Teva, Actavis, Mallinckrodt, Trigen Laboratories, Impax, Rhodes Pharmaceuticals, Sun Pharmaceutical, and other ANDA sponsors, depending on the reference product and market period. Product-level litigation and approval status must be assessed separately because an applicant may challenge one dosage form without affecting another.

The competitive risk is highest where:

• The reference product has high sales and limited generic supply.
• The dosage form has manageable bioequivalence requirements.
• The formulation uses commercially available polymers.
• The ANDA does not require a novel device or complex delivery system.
• The applicant can reproduce the reference dissolution profile across multiple pH conditions.

How strong is the patent estate for methylphenidate extended-release?

Patent strength is strongest for complex release systems and weakest for conventional matrix tablets using well-established excipients.

Patent feature	Relative strength	Reason
Broad OROS architecture	High historically	Requires specialized tablet and coating technology
Specific polymer ratio or coating weight	Moderate	May be designed around with alternative polymers or process conditions
Defined dissolution profile	Moderate to high	Can support infringement claims but may create equivalence challenges
Taste-masked microparticles	Moderate	Commercially valuable but vulnerable to formulation alternatives
Generic matrix composition	Low to moderate	Crowded prior art and multiple design-around paths
Manufacturing process	Moderate	Difficult to detect infringement but can restrict technical options
Method-of-use claim	Variable	Scope depends on approved labeling and patent-use code

The strongest commercial position usually comes from a combination of formulation patents, manufacturing know-how, regulatory exclusivity, trademarks, controlled-substance distribution controls, and physician familiarity.

What commercial opportunities exist for excipient suppliers?

Specialty release-controlling polymers

Suppliers can target validated grades of polyethylene oxide, hypromellose, ethylcellulose, methacrylate copolymers, and coating systems. Differentiation depends on:

• Consistent molecular-weight distribution.
• Low peroxide and impurity levels.
• Controlled viscosity.
• Reliable aqueous or organic processing.
• Documentation for U.S. regulatory submissions.
• Multi-site supply capability.

Excipient platforms for pediatric products

Pediatric methylphenidate products create demand for:

• Low-sugar sweetener systems.
• Flavor systems compatible with bitter drug substances.
• Ion-exchange resins.
• Compressible mannitol.
• Low-moisture ODT excipients.
• Suspension stabilizers.
• Preservative systems.
• Sprinkle-compatible coating materials.

A supplier that can provide a complete taste-masking and release-control package has greater commercial leverage than a supplier selling an isolated excipient.

Coating and multiparticulate CDMO services

Small and mid-sized pharmaceutical companies may lack fluid-bed coating, drug layering, capsule filling, or multiparticulate characterization capability. CDMOs can offer:

• Formulation screening.
• Bead coating.
• Dissolution method development.
• Scale-up.
• Controlled-substance handling.
• Stability manufacturing.
• Exhibit batches for ANDA or 505(b)(2) filings.

505(b)(2) product development

A 505(b)(2) strategy can support differentiated products with new dosage forms, administration timing, pediatric usability, or improved adherence. Commercial targets include:

• Lower-volume oral suspensions.
• Extended-release chewable tablets.
• Sprinkle capsules with improved palatability.
• ODTs for patients who cannot swallow tablets.
• Alternate release profiles for evening or early-morning coverage.

The regulatory burden is greater than for a conventional immediate-release generic but may be lower than developing a new molecular entity. Clinical bridging, pharmacokinetic studies, food-effect studies, and comparative dissolution remain central.

What manufacturing and intellectual-property barriers affect new entrants?

Methylphenidate is a Schedule II controlled substance in the United States. Manufacturing requires controlled-substance registration, quota management, security controls, inventory reconciliation, and specialized distribution procedures.[12]

Technical barriers include:

• High-potency drug layering and containment.
• Uniform distribution of drug across multiparticulates.
• Coating defects that cause dose dumping.
• Segregation of different bead populations.
• Maintaining suspension uniformity.
• Controlling residual solvents.
• Reproducing the reference product’s food-effect profile.
• Meeting dissolution specifications after scale-up.
• Preventing crushing or manipulation from altering release.

The most attractive entry route depends on the product. An ANDA for a simple capsule may have a lower development burden than an ODT, liquid suspension, or osmotic tablet. A 505(b)(2) product can command a premium if it solves a clear administration or adherence problem.

How does methylphenidate extended-release compare with amphetamine extended-release products?

Methylphenidate ER competes directly with mixed amphetamine salts ER, lisdexamfetamine, dexmethylphenidate ER, and newer stimulant formulations.

Attribute	Methylphenidate ER	Amphetamine ER
Main formulation opportunity	Release timing, pediatric delivery, multiparticulates	Prodrug conversion, bead systems, complex salts
Generic competition	Established for several presentations	Established but product-specific
Excipient differentiation	High in liquid, ODT, chewable, and delayed-onset products	High in prodrug and multi-pulse systems
Controlled-substance burden	Schedule II	Schedule II
Key clinical commercial factor	Duration and timing of symptom control	Duration, onset, and tolerability
Patent risk	Delivery architecture and dosage form	Prodrug chemistry, release system, and formulation

Methylphenidate products have a relatively mature active-ingredient market, so commercial value is more likely to come from administration and release differentiation than from composition-of-matter protection.

What generic launch scenarios exist for methylphenidate extended-release?

Three launch scenarios are commercially relevant.

Early Paragraph IV launch

A successful Paragraph IV challenge can produce 180-day exclusivity for the first eligible ANDA applicant, subject to forfeiture rules. The applicant may launch at risk after patent expiry, settlement, or a favorable court outcome.[11]

Post-expiry conventional generic entry

Once relevant patents expire and regulatory requirements are met, several manufacturers may enter. Price erosion can be rapid, especially for standard tablets and capsules with multiple approved ANDAs.

Limited-competition complex generic entry

Liquid suspensions, ODTs, chewables, delayed-onset products, and osmotic systems may retain higher margins because fewer manufacturers can reproduce the formulation and manufacturing process. Supply interruptions can also support premium pricing, although controlled-substance quota constraints may limit volume expansion.

What is the revenue exposure from methylphenidate extended-release products?

Revenue exposure is concentrated in the branded formulations with differentiated release profiles and pediatric administration options. The most defensible commercial segments are:

• Once-daily products with clear adherence advantages.
• Delayed-onset evening dosing.
• Liquid formulations for children who cannot swallow pills.
• ODT products that eliminate the need for water.
• Chewable tablets with acceptable taste.
• Products with stable and predictable coverage across the school or workday.

Commodity generic tablets face greater price pressure. Branded products can preserve value through clinical positioning, supply reliability, payer contracting, patient support, and differentiated administration rather than through methylphenidate exclusivity alone.

What is the best excipient strategy for a new methylphenidate extended-release product?

The strongest strategy is to select the target market before selecting the excipient system.

Commercial target	Preferred formulation platform	Priority excipient capabilities
Low-cost generic capsule	Coated multiparticulates	Reliable ethylcellulose or methacrylate coating
Pediatric liquid	Resin complex suspension	Taste masking, suspending system, redispersibility
Premium pediatric product	Chewable or ODT	Palatability, rapid disintegration, controlled-release microparticles
Early-morning symptom control	Delayed-release multiparticulates	Enteric polymer control and overnight stability
Long-duration tablet	Osmotic or high-performance matrix	Swellable polymers, osmogen, membrane coating
505(b)(2) differentiated product	Novel release or administration profile	Integrated excipient and process intellectual property

A commercial formulation should be designed around a measurable product claim: longer coverage, delayed onset, no-water administration, improved taste, flexible sprinkling, or reduced dosing frequency. Excipient choices should support that claim through dissolution, pharmacokinetic, stability, and human-use data.

Key Takeaways

• Methylphenidate extended-release is a portfolio of distinct dosage forms, not one unified product.
• The main excipient opportunities are controlled-release polymers, multiparticulate coatings, taste-masking systems, ODT excipients, suspension stabilizers, and osmotic delivery materials.
• Patent risk centers on release architecture, coating compositions, dissolution profiles, dosage forms, and manufacturing processes.
• Orange Book analysis must be performed by reference-listed drug and dosage form.
• Generic competition is strongest for conventional capsules and tablets and less predictable for liquid, chewable, ODT, delayed-onset, and osmotic products.
• Schedule II controls, quota management, specialized manufacturing, and controlled-substance handling raise entry barriers.
• The most attractive commercial opportunities combine differentiated administration with excipient-enabled intellectual property.
• A 505(b)(2) strategy is most credible where the product provides a clear improvement in timing, palatability, pediatric usability, or dosing convenience.

FAQs

Can a new excipient create patent protection for methylphenidate extended release?

Yes. A new excipient alone may not provide strong protection, but a patent can protect its use in a defined release system, particle architecture, dissolution profile, taste-masking structure, or manufacturing process.

Which methylphenidate extended-release dosage form is hardest to copy?

Osmotic tablets and delayed-onset multiparticulate products are generally more difficult to reproduce than conventional matrix tablets because they require specialized manufacturing and tighter control of release kinetics.

Are methylphenidate extended-release liquids easier to develop than tablets?

No. Liquids avoid tablet-swallowing problems but create challenges in suspension stability, dose uniformity, taste masking, microbial control, preservative compatibility, and resuspension performance.

Do polymer excipients affect methylphenidate bioequivalence?

Yes. Polymer type, viscosity, coating thickness, plasticizer content, particle size, and pore formation can alter dissolution and systemic exposure. These variables may affect both in vitro equivalence and pharmacokinetic performance.

Is biosimilar competition relevant to methylphenidate extended release?

No. Methylphenidate is a chemically synthesized small molecule, so competition proceeds through generic, ANDA, authorized-generic, or 505(b)(2) pathways rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Concerta (methylphenidate hydrochloride) extended-release tablets prescribing information.

2. U.S. Food and Drug Administration. (2024). Ritalin LA (methylphenidate hydrochloride) extended-release capsules prescribing information.

3. U.S. Food and Drug Administration. (2024). Metadate CD (methylphenidate hydrochloride) extended-release capsules prescribing information.

4. U.S. Food and Drug Administration. (2024). Aptensio XR (methylphenidate hydrochloride) extended-release capsules prescribing information.

5. U.S. Food and Drug Administration. (2024). Quillivant XR (methylphenidate hydrochloride) extended-release oral suspension prescribing information.

6. U.S. Food and Drug Administration. (2024). Quillichew ER (methylphenidate hydrochloride) extended-release chewable tablets prescribing information.

7. U.S. Food and Drug Administration. (2024). Jornay PM (methylphenidate hydrochloride) extended-release capsules prescribing information.

8. U.S. Food and Drug Administration. (2024). Cotempla XR-ODT (methylphenidate hydrochloride) extended-release orally disintegrating tablets prescribing information.

9. U.S. Patent No. 5,837,284. (1998). Controlled-release tablet.

10. U.S. Patent No. 6,919,373. (2005). Methylphenidate osmotic dosage form.

11. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

12. U.S. Drug Enforcement Administration. (2024). Controlled substances schedules and regulatory requirements.